The inverse association between tuberculin responses and atopic disorder

Science

Volumn 275, Issue 5296, 1997, Pages 77-79

  Shirakawa, Taro ^a   Enomoto, Tadao ^b   Shimazu, Shin Ichiro ^c   Hopkin, Julian M ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; TUBERCULIN;

ADOLESCENT; ARTICLE; ASTHMA; ATOPY; DELAYED HYPERSENSITIVITY; ENVIRONMENTAL FACTOR; HELPER CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; JAPAN; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SCHOOL CHILD; TUBERCULIN TEST;

ADOLESCENT; ASTHMA; BCG VACCINE; CHILD; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYTOKINES; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; INTERFERON TYPE II; JAPAN; MALE; TH1 CELLS; TH2 CELLS; TUBERCULIN; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0031014668     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.275.5296.77     Document Type: Article

References (35)

1. R. Ishizaka, Clin. Allergy 1, 9 (1971).
2. B. Burrows, F. D. Martinez, M. Halonen, R. A. Barbee, M. G. Cline, N. Engl. J. Med. 320, 271 (1989).
3. J. M. Hopkin, Pediatr. Allergy lmmunol. 6, 139 (1995).
4. I. Aebischer and B. M. Stadler, Adv. lmmunol. 61, 341 (1996); J. M. Carballido, N. Carballido-Perrig, G. Terres, C. H. Heusser, K. Blaser, Eur. J. lmmunol. 22, 1357 (1992).
5. I. Aebischer and B. M. Stadler, Adv. lmmunol. 61, 341 (1996); J. M. Carballido, N. Carballido-Perrig, G. Terres, C. H. Heusser, K. Blaser, Eur. J. lmmunol. 22, 1357 (1992).
6. I. N. Bruce, R. W. Harland, N. A. McBride, J. MacMahon, Q. J. Med. 86, 425 (1993); F. SchultzLarsen, Monogr. Allergy 31, 9 (1993); E. von Mutius, C. Fritsch, S. K. Weiland, G. Roell, H. Magnussen, Br. Med. J. 305, 1395 (1992).
7. I. N. Bruce, R. W. Harland, N. A. McBride, J. MacMahon, Q. J. Med. 86, 425 (1993); F. SchultzLarsen, Monogr. Allergy 31, 9 (1993); E. von Mutius, C. Fritsch, S. K. Weiland, G. Roell, H. Magnussen, Br. Med. J. 305, 1395 (1992).
8. I. N. Bruce, R. W. Harland, N. A. McBride, J. MacMahon, Q. J. Med. 86, 425 (1993); F. SchultzLarsen, Monogr. Allergy 31, 9 (1993); E. von Mutius, C. Fritsch, S. K. Weiland, G. Roell, H. Magnussen, Br. Med. J. 305, 1395 (1992).
9. D. A. Waite, E. F. Eyles, S. L. Tonkin, T. V. O'Donnell, Clin. Allergy 10, 71 (1980); J. Morrison-Smith and S. Cooper, Postgrad. Med. J. 57, 774 (1981).
10. D. A. Waite, E. F. Eyles, S. L. Tonkin, T. V. O'Donnell, Clin. Allergy 10, 71 (1980); J. Morrison-Smith and S. Cooper, Postgrad. Med. J. 57, 774 (1981).
11. H. E. Wickmann, Clin. Exp. Allergy 26, 621 (1996).
12. V. H. Springett, J. H. Darbyshire, A. J. Nunn, I. Sutherland, J. Epidemiol. Community Health 42, 370 (1988); R. Doll, Am. J. Public Health 82, 933 (1992); M. Burnet and D. O. White, Natural History of Infectious Disease (Cambridge Univ. Press, Cambridge, 1972).
13. V. H. Springett, J. H. Darbyshire, A. J. Nunn, I. Sutherland, J. Epidemiol. Community Health 42, 370 (1988); R. Doll, Am. J. Public Health 82, 933 (1992); M. Burnet and D. O. White, Natural History of Infectious Disease (Cambridge Univ. Press, Cambridge, 1972).
14. V. H. Springett, J. H. Darbyshire, A. J. Nunn, I. Sutherland, J. Epidemiol. Community Health 42, 370 (1988); R. Doll, Am. J. Public Health 82, 933 (1992); M. Burnet and D. O. White, Natural History of Infectious Disease (Cambridge Univ. Press, Cambridge, 1972).
15. E. von Mutius et al., Br. Med. J. 308, 692 (1994).
16. D. T. Fearon and R. M. Locksley, Science 272, 50 (1996); S. H. E. Kaufmann, Annu. Rev. lmmunol. 11, 129 (1993).
17. D. T. Fearon and R. M. Locksley, Science 272, 50 (1996); S. H. E. Kaufmann, Annu. Rev. lmmunol. 11, 129 (1993).
18. A. M. Cooper et al., Immunology 84, 423 (1995); V. Donckier et al., J. lmmunol. 153, 2361 (1994); L. Xu and P. Rothman, Int. lmmunol. 6, 515 (1994).
19. A. M. Cooper et al., Immunology 84, 423 (1995); V. Donckier et al., J. lmmunol. 153, 2361 (1994); L. Xu and P. Rothman, Int. lmmunol. 6, 515 (1994).
20. A. M. Cooper et al., Immunology 84, 423 (1995); V. Donckier et al., J. lmmunol. 153, 2361 (1994); L. Xu and P. Rothman, Int. lmmunol. 6, 515 (1994).
21. G. P. Youmans, Am. Rev. Respir. Dis. 111, 109 (1975).
22. P. E. Fine, J. A. Sterne, J. M. Ponnighaus, R. J. Rees, Lancet 344, 1245 (1994).
23. 6 colony-forming units (CFU) of attenuated bovine M. tuberculosis (BCG, Tokyo 172 strain, Japan BCG Laboratory). At 3 months of age, 97 to 98% of the children (groups 1 to 4 in Table 1) were tuberculin-negative and received BCG.
24. H1 cytokine IFN-γ (r = -0.567; P = 0.001).
25. H1 cytokine IFN-γ (r = -0.567; P = 0.001).
26. N. S. Galbraith, A. Hanson, R. Shoulman, D. W. Andres, D. B. Lee, Br. Med. J. 1, 647 (1972); T. Oettinger, A. Holm, I. M. Mtoni, A. B. Andersen, K. Hasloov, Infect. Immun. 63, 4613 (1995). As a rule, positive tuberculin responses are caused by infection with M. tuberculosis, whereas intermediate responses are caused by exposure to nontuberculous mycobacteria or immunization with BCG. We cannot exclude the possibility that some of the conversions to tuberculin positivity after 6 years of age might be attributable to a second immunization with BCG, especially because the Tokyo 172 BCG used is strongly immunogenic, having retained the gene for the major antigen, MPT 64; nor do we know what role environmental mycobacteria may have played in this semirural environment.
27. N. S. Galbraith, A. Hanson, R. Shoulman, D. W. Andres, D. B. Lee, Br. Med. J. 1, 647 (1972); T. Oettinger, A. Holm, I. M. Mtoni, A. B. Andersen, K. Hasloov, Infect. Immun. 63, 4613 (1995). As a rule, positive tuberculin responses are caused by infection with M. tuberculosis, whereas intermediate responses are caused by exposure to nontuberculous mycobacteria or immunization with BCG. We cannot exclude the possibility that some of the conversions to tuberculin positivity after 6 years of age might be attributable to a second immunization with BCG, especially because the Tokyo 172 BCG used is strongly immunogenic, having retained the gene for the major antigen, MPT 64; nor do we know what role environmental mycobacteria may have played in this semirural environment.
28. Japanese Ministry of Health and Welfare, Trends of Health and Welfare in Japan, 1994 (Ministry of Health and Welfare, Tokyo, 1995).
29. G. B. Mackaness, P. H. Lagrange, T. lshibashi, J. Exp. Med. 139, 1540 (1974).
30. E. J. Pearce, P. Caspar, J.-M. Grzych, F. A. Lewis, A. Sher, ibid. 173, 159(1991).
31. S. O. Shaheen et al., Lancet 347, 1792 (1996).
32. R. W. Baker, A. Zumla, G. A. W. Rook, Q. J. Med. 89, 387 (1996); J. M. Grange, ibid., p. 323; P. G. Holt, Toxicol. Lett. 86, 205 (1996).
33. R. W. Baker, A. Zumla, G. A. W. Rook, Q. J. Med. 89, 387 (1996); J. M. Grange, ibid., p. 323; P. G. Holt, Toxicol. Lett. 86, 205 (1996).
34. R. W. Baker, A. Zumla, G. A. W. Rook, Q. J. Med. 89, 387 (1996); J. M. Grange, ibid., p. 323; P. G. Holt, Toxicol. Lett. 86, 205 (1996).
35. We thank the school doctors of Hidaka Medical Association for help with sample collections, and T. Yamashita and F. Kurimoto (Mitsubishi), T. Onishi (Shinogi), and K. Kato (DPC Japan) for help with serological assays. We thank the students for participating and their teachers and school nurses for their assistance. Supported in part by Mitsubishi Chemical Company (Tokyo).